Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05455606 · ClinicalTrials.gov registry record · NA
Does the Use of a Genomic Tumor Board Increase the Number of Patients Who Receive Genome-Informed Treatment
A NA study of Advanced Malignant Solid Neoplasm and Metastatic Malignant Solid Neoplasm, sponsored by SWOG Cancer Research Network.
- Active
- Registry status
- NA
- Development phase
- 1,284
- Enrollment target
- 20
- Study locations
NCT05455606: Active NA study of Advanced Malignant Solid Neoplasm and Metastatic Malignant Solid Neoplasm, sponsored by SWOG Cancer Research Network.
NCT05455606 is a NA study of Advanced Malignant Solid Neoplasm and Metastatic Malignant Solid Neoplasm that is active but no longer recruiting, run by SWOG Cancer Research Network. The registered enrollment target is 1,284 participants, above the 165-participant average among 108 other Advanced Malignant Solid Neoplasm trials with a reported enrollment target (678% higher). The trial reports 20 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05455606, a NA study of Advanced Malignant Solid Neoplasm and Metastatic Malignant Solid Neoplasm, is active but no longer recruiting, sponsored by SWOG Cancer Research Network.
- ACTIVE NOT RECRUITING
- Registry status
- NA
- Development phase
- 1,284 participants
- Enrollment target
- 20
- Study locations
Study Summary
This clinical trial studies how well an educationally enhanced genomic tumor board (EGTB) intervention works to increase the number of patients with solid tumors that have come back (recurrent), do not respond to treatment (refractory), have spread to other parts of the body (metastatic), or are newly diagnosed and spread to other parts of the body (advanced) who receive genome-informed treatment. Genome-informed treatment refers to treatment based on the information found in genomic tumor test results. This study compares the usual approach to reviewing genomic tumor test results with the approach of having a genomic tumor board (GTB) review the test results. A GTB is team of doctors and scientists that have experience in understanding genomic changes and review genomic tumor test results. The tumor board helps to suggest whether there are other cancer treatment options based on patient genetic test results. The usual approach is to review genomic tumor test results without the GTB being involved. This study may help researchers learn if using a GTB enhances the treatment decision making process within 6 months of joining the study. This study may also help researchers learn if using the GTB increases doctors' understanding of genomic tumor test results and increases doctors' comfort level with genomic tumor tests.
Primary Outcome
Evidence-based genome-informed therapy is defined as the use of a treatment that targets a genomic variant for which there is sufficient data to support actionability. This is a patient-specific measure determined through blinded central review of patient data, following the schemas in the protocol. An independent panel of investigators blinded to the study arm assignment of the study participant will evaluate redacted data from each subject for determination of the primary endpoint. Data suppor
Conditions Studied
Interventions
- OTHER Best Practice
- OTHER Educational Intervention
- OTHER Interview
- PROCEDURE Genomic Profile
- OTHER Chart Abstraction
Study Locations (20)
Illinois
- Illinois CancerCare-Bloomington - Bloomington
- Illinois CancerCare-Canton - Canton
- Carle at The Riverfront - Danville
- Illinois CancerCare-Galesburg - Galesburg
- Carle Physician Group-Mattoon/Charleston - Mattoon
- Illinois CancerCare-Ottawa Clinic - Ottawa
- Illinois CancerCare-Peoria - Peoria
- Carle Cancer Center - Urbana
Hawaii
- Hawaii Cancer Care Inc - Waterfront Plaza - Honolulu
- Queen's Medical Center - Honolulu
- Straub Clinic and Hospital - Honolulu
- University of Hawaii Cancer Center - Honolulu
- Kapiolani Medical Center for Women and Children - Honolulu
- Hawaii Cancer Care - Westridge - ‘Aiea
- Pali Momi Medical Center - ‘Aiea
Iowa
- Iowa Methodist Medical Center - Des Moines
- Medical Oncology and Hematology Associates-Des Moines - Des Moines
Arizona
- Cancer Center at Saint Joseph's - Phoenix
Georgia
- Lewis Cancer and Research Pavilion at Saint Joseph's/Candler - Savannah
Idaho
- Kootenai Clinic Cancer Services - Post Falls - Post Falls
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,284 participants |
| Start Date | 2022-10-14 |
| Est. Completion | 2027-03-01 |
| Phase | NA |
What the registry record for NCT05455606 still lists
NCT05455606 is an interventional study that assigns participants to a tested intervention. Its 1,284 participants enrollment target places it among the larger protocols in the corpus, above the 165-participant average among 108 other Advanced Malignant Solid Neoplasm trials with a reported enrollment target (678% higher).
The record links to 4 conditions, with Advanced Malignant Solid Neoplasm appearing as the primary indexed condition, and to 5 interventions - of which Best Practice is the first listed.
NCT05455606 names 20 study sites across 6 states, led by Illinois, Hawaii, Iowa.
Frequently Asked Questions
What is clinical trial NCT05455606 about?
NCT05455606 is a clinical study titled "Does the Use of a Genomic Tumor Board Increase the Number of Patients Who Receive Genome-Informed Treatment". This clinical trial studies how well an educationally enhanced genomic tumor board (EGTB) intervention works to increase the number of patients with solid tumors that have come back (recurrent), do not respond to treatment (refractory), have spread to other parts of the body (metastatic), or are new...
What is the current status of trial NCT05455606?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 1,284 participants. The study started on 2022-10-14. Estimated completion is 2027-03-01.
What conditions does trial NCT05455606 study?
This clinical trial studies the following conditions: Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm, Refractory Malignant Solid Neoplasm, Recurrent Malignant Solid Neoplasm.
What interventions are being tested in trial NCT05455606?
The interventions under investigation include: Best Practice (OTHER), Educational Intervention (OTHER), Interview (OTHER), Genomic Profile (PROCEDURE), Chart Abstraction (OTHER).
Who is sponsoring clinical trial NCT05455606?
This trial is sponsored by SWOG Cancer Research Network, which has 270 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05455606 being conducted?
This trial has 20 study locations across Arizona, Georgia, Hawaii, Idaho, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Advanced Malignant Solid Neoplasm
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05455606's enrollment target sits among peer trials
1,284 4th of 108 higher than 105 of 108 other Advanced Malignant Solid Neoplasm trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Advanced Malignant Solid Neoplasm trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Fasting Mimicking Diet for Reducing Immune Related Adverse Events for Cancer Patients on Immune Checkpoint Inhibitors, FMD-ICI Trial
RECRUITING · NA
-
Educational Tools for the Improvement of Early Advance Care Planning in Adolescents and Young Adults With Advanced Solid Tumors and High-Grade Brain Tumors
RECRUITING · NA
-
Technology-Enhanced Palliative Care for Advanced Cancer Patients
ACTIVE NOT RECRUITING · NA
-
Mindfulness-Based Intervention for Latino Cancer Patients and Their Caregivers
ACTIVE NOT RECRUITING · NA
-
Learning Collaborative Versus Technical Assistance in Delivering a Palliative Care Program to Patients With Advanced Cancer and Their Caregivers
ACTIVE NOT RECRUITING · NA
-
IACS-6274 With or Without Bevacizumab and Paclitaxel for the Treatment of Advanced Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06626022 · 1,284 participants · Phase 3
Screening for Prostate Cancer Using High Resolution Micro-ultrasound Versus Multiparametric Magnetic Resonance Imaging.
- NCT03970447 · 1,280 participants · Phase 2
A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma
- NCT06468228 · 1,280 participants · Phase 3
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa
- NCT07207811 · 1,280 participants · Phase 3
CLEOPATTRA: A Research Study to Look at the Effects of Treatment With a Medicine Called Coramitug (NNC6019-0001) in People With Heart Failure Due to Transthyretin Amyloid (ATTR) Amyloidosis
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI